Luke Gill, B.Sc., M.Sc., MBA
Vice President, Oncology
Luke Gill is the head of Oncology Clinical Development Services at Premier Research. He works collaboratively with biotech sponsors, the scientific community, and other stakeholders to develop and implement strategic approaches to early phase oncology development and CAGT trials. As a drug development expert, Gill has more than 20 years of experience in developing, leading, and executing complex multidisciplinary research programs.
Peter Larson, M.D.
Executive Medical Director
Peter Larson is the executive medical director for Hematology-Oncology at Premier Research. Dr. Larson supports the drug development work of the innovative biotech companies that compose most of Premier Research’s customer base, bringing to the role over 20 years of clinical development and medical affairs experience. He has a background spanning large pharma, startup biotech, and contract research.
As the world emerges from the pandemic of novel coronavirus disease (COVID-19), the treatment need for cancer patients is greater than ever. In this episode of Premier Voices, we present highlights from a recent Premier Research webinar on managing ongoing cell and gene therapy (CAGT) trials while looking ahead to the future of oncology research.
In this presentation by Premier’s Vice President of Oncology Luke Gill and Executive Medical Director Peter Larson, you’ll learn:
- How the newest cell and gene therapies are being used to treat tumors, including a review of the science and pathophysiology associated with CAGT
- Which design and operational considerations need to be addressed when planning an early-phase trial
- How the pandemic has impacted the oncology clinical trial environment